Article Detail

Home > Article Detail
  • P-ISSN 2233-4203
  • E-ISSN 2093-8950

Isotope-Dilution Mass Spectrometry for Quantification of Urinary Active Androgens Separated by Gas Chromatography

Mass Spectrometry Letters / Mass Spectrometry Letters, (P)2233-4203; (E)2093-8950
2010, v.1 no.1, pp.29-32
https://doi.org/10.5478/MSL.2010.1.1.029
Lee Su Hyeon (Korea Institute of Science and Technology, Yonsei University)
Choi Man Ho (Korean Institute of Science and Technology)
Lee Won-Yong (Yonsei University)
Chung Bong Chul (Korea Institute of Science and Technology)
  • Downloaded
  • Viewed

Abstract

Cross reacting antibodies can cause an overestimation of the results of immunoassays. Therefore, alternative methodsare needed for the accurate quantification of steroids. Gas chromatography combined with isotope-dilution mass spectrometry(GC-IDMS) is developed to quantify urinary active androgens, testosterone, epitestosterone and dihydrotestosterone, which areclinically relevant androgens to both hair-loss and prostate diseases. The method devised involves enzymatic hydrolysis with β-glucuronidase, solid-phase extraction, liquid-liquid extraction using methyl tert-butyl ether and subsequent conversion to pentafluorophenyldimethylsilyl-trimethylsilyl (flophemesyl-TMS) derivatives for sensitive and selective analysis in selected-ionmonitoring mode. Flophemesyl-TMS derivatization not only eliminates matrix interference but also has a good peak resolutionwithin a 6 min-run. A selective and sensitive GC technique with flophemesyl-TMS derivatives also allows accurate quantitativeanalysis of three active androgens when combined with IDMS. The limit of quantification of the three analytes was <50 pg/mL,and extraction recoveries ranged from 91.9 to 102.1%. The precision and accuracy were 1.2~6.5% and 89.0~106.7%, respectively. This GC-IDMS method can be useful for evaluating the drug efficacy and monitoring the biological processes responsiblefor male-pattern baldness and prostate diseases.

keywords
Androgen, Testosterone, Isotope-dilution, GC-MS, Drug efficacy


Reference

1

Nuck, B. A. (1987). . J. Invest. Dermatol, 89, 209-.

2

Starka, L. (1993). . Endocr. Regul, 27, 43-.

3

Choi, M. H. (2001). . J. Invest. Dermatol, 116, 57-.

4

Choi, M. H. (2003). . Clin. Chem, 49, 322-.

5

Luu-The, V. (2008). . Best Pract, Res. Clin. Endocrinol. Metabol, 22, 207-.

6

Taieb, J. (2003). . Clin. Chem, 49, 1381-.

7

Wang, C. (2004). . J. Clin. Endocrinol. Metab, 89, 2936-.

8

Moon, J.-Y. (2008). . Steroids, 73, 1090-.

9

Moon, J.-Y. (2010). . Cancer Epidemiol. Biomarkers Prev, 19, 388-.

10

Moon, J.-Y. (2009). . J. Am. Soc. Mass Spectrom, 20, 1626-.

11

Van Uytfanghe, K. (2004). . Clin. Chem, 50, 2101-.

12

Cawood, M. L. (2005). . Clin. Chem, 51, 1472-.

13

Tai, S. S. (2007). . Anal. Bioanal. Chem, 388, 1087-.

14

Wang, W. (2003). . Anal. Chem, 75, 4818-.

15

Thienpont, L. M. (1994). . Anal. Chem, 15, 4116-.

16

Choi, M. H. (1999). . Analyst, 124, 675-.

17

Ha, Y. W. (2009). . J. Chromatogr. B, 877, 4125-.

Submission Date
2010-11-14
Revised Date
2010-11-25
Accepted Date
2010-11-27
상단으로 이동

Mass Spectrometry Letters